Asia Pacific trial sector poised for continued growth, says Novotech

By Gareth Macdonald

- Last updated on GMT

Related tags: Asia pacific, Contract research organization, United states

The Asia Pacific trial sector grew during the global economic downturn as sponsors sought to improve access to patients, cut costs and improve data quality according to Novotech CEO Alek Safarian.

Safarian told Outsourcing-pharma there had been a four-fold increase in trials being conducted by contract research organisations (CRO) in a number of countries in Asia Pacific, with India, Taiwan and Novotech’s base, Australia, seeing the biggest gains.

He also predicted that, while in common with other developing clinical trial hubs like Latin America and Central and Eastern Europe (CEE) the Asia Pacific market will continue to expand, the three billion potential patients in the region make it a unique opportunity for sponsors.

Safarian also suggested that factors like Asia Pacific's ethnic diversity and its reverse seasonality, with respect to the Northern hemisphere, are becoming increasingly attractive to global pharmaceutical firms keen to tap emerging pharmaceutical markets.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars